HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines

Biochemical and Biophysical Research Communications

Volumn 387, Issue 2, 2009, Pages 336-341

  Flis, Sylwia ^a   Gnyszka, Agnieszka ^a   Spławiński, Jacek ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Apoptosis; Colorectal cancer; HDACi; MS275; Oxaliplatin; SBHA; Synergism

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXALIPLATIN; SUBERIC BISHYDROXAMATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CHROMATIN CONDENSATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; ORGANOPLATINUM COMPOUNDS; PYRIDINES;

EID: 67949123074     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.017     Document Type: Article

References (16)

1. Dokmanovic M., Clarke C., and Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5 (2007) 981-989
2. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 66 (2003) 1537-1545
3. Frew J., Johnstone R.W., and Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280 (2009) 125-133
4. Gessner P.K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105 (1995) 161-179
5. Chou T.C., and Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4 (1983) 445-450
6. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
7. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., Steele Jr. G.D., and Chen L.B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA 88 (1991) 3671-3675
8. Mahyar-Roemer M., Katsen A., Mestres P., and Roemer K. Resveratrol induces colon tumor cell apoptosis independently of p53 and proceed by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer 94 (2001) 615-622
9. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treatment Rev. 32 (2006) 157-165
10. Di Gennaro E., Bruzzese F., Caraglia M., Abruzzese A., and Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26 (2004) 435-441
11. Eot-Houllier G., Fulcrand G., Magnaghi-Jaulin L., and Jaulin Ch. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 274 (2009) 169-176
12. Laurent A., Nicco C., Chéreau C., Goulvestre C., Alexandre J., Alves A., Lévy E., Goldwasser F., Panis Y., Soubrane O., Weill B., and Batteux F. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 65 (2005) 948-956
13. CIP1/WAF1 1. Cancer Res. 63 (2003) 3637-3645
14. Martirosyan A., Leonard S., Shi X., Griffith B., Gannett P., and Strobl J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J. Pharmacol. Exp. Ther. 317 (2006) 546-552
15. Carew J., Giles F., and Nawrocki S. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269 (2008) 7-17
16. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98 (2001) 10833-10838